Chris Alison Chou, MD
Sleep Medicine · Kirkland
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
Offices
2 locations · King County Public Hospital District No 2 · Stanford Health Care
Hospitals listed: Evergreenhealth Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Chou’s office to ask if they take your plan before you enroll.
State licence records
1 licence
- Washington MD.MD.61157048Physician And Surgeon License · since 2021 · expires 2028-08-23ActiveNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Evergreenhealth Medical CenterKirkland, WAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of EvergreenHealth, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.335, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
See every measure and the patient survey for Evergreenhealth Medical Center
Behind the star rating — Deaths: 3 better, 4 the same, 0 worse of 7 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 1 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.335 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.1 (0.11 to 2.09) · 1,003 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.75 (0.44 to 1.07) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 158.5 (106.49 to 210.51) · 62 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 80 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 138 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.2 · 650 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.6 · 512 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.7 · 419 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.6 · 3,509 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,473 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.35 (0.16 to 0.54) · 6,368 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.57 (0.58 to 4.56) · 1,401 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.51 (0 to 3.16) · 559 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.37 (0.83 to 3.91) · 1,295 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 5.67 (0 to 12.54) · 573 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.57 (0.84 to 8.31) · 535 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 268 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.33 (0 to 0.99) · 5,577 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.6 · 202 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.642 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.708 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.331 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.2 · 197 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.9 · 942 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -28.3 · 136 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -0.2 · 719 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 26.7 · 521 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.9 · 708 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.8 (3.1 to 7.7) · 57 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.3 (6.3 to 13.8) · 57 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 200 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.7 · 137 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14 (10.5 to 18.7) · 566 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.9 to 1.4) · 1,099 cases | No different | Jan 2024 – Dec 2024 |
What patients said (481 patients answered, 19% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 72% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 88% |
| Patients who gave a rating of "9" or "10" (high) | 77% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 74% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 57% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$26,352
Medicare paid this office $26,352 for 167 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| New patient visit (45+ min) | 70 | $6,861 | $98 |
| Return visit (30+ min) | 49 | $5,612 | $77 |
| Short return visit (20+ min) | 67 | $4,081 | $50 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 21 | $2,075 | $94 |
| Sleep study including heart rate, breathing, airflow, and effort | 58 | $2,048 | $35 |
See all 7 services
| New patient visit (45+ min) | 70 | $6,861 | $98 |
| Return visit (30+ min) | 49 | $5,612 | $77 |
| Short return visit (20+ min) | 67 | $4,081 | $50 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 21 | $2,075 | $94 |
| Sleep study including heart rate, breathing, airflow, and effort | 58 | $2,048 | $35 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 98 | $2,036 | $14 |
| Sleep study in sleep lab (6 years or older) | 22 | $1,796 | $82 |
Who their Medicare patients are
167 Original Medicare patients in 2024. Average age 74 · Women 51% · Health risk score 0.96. At or below the middle of the specialty; the typical sleep medicine clinician is at 1.21.
Conditions among them: High blood pressure 64% · Coronary heart disease 32% · Atrial fibrillation 29% · Diabetes 23% · Depression 20% · Cancer 16% · Heart failure 14% · Chronic kidney disease 13% · COPD 11%.
The office billed $87,222, Medicare allowed $36,001 and paid $26,352; for 498 services of 11 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 167 | 498 | 74 | 0.96 | $87,222 | $26,352 |
| 2023 | 132 | 282 | 74 | 0.97 | $59,632 | $20,972 |
| 2022 | 102 | 140 | 72 | 0.99 | $50,490 | $13,317 |
| 2021 | 46 | 57 | 67 | 1.26 | $21,848 | $6,439 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| New patient visit (45+ min) | 74 | $7,692 | $104 |
| Short return visit (20+ min) | 49 | $3,249 | $52 |
| New patient visit (60+ min) | 14 | $1,963 | $140 |
| Sleep study including heart rate, breathing, airflow, and effort | 57 | $1,918 | $33 |
| Return visit (30+ min) | 20 | $1,753 | $73 |
| Sleep study in sleep lab (6 years or older) | 14 | $1,486 | $99 |
2022: 4 services
| New patient visit (45+ min) | 22 | $2,277 | $104 |
| New patient visit (60+ min) | 13 | $1,649 | $127 |
| Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 15 | $1,010 | $67 |
| Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | 14 | $379 | $27 |
Drugs they prescribed that Part D paid
$7,380
Pharmacies billed $7,380 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 14% of their Part D prescriptions (25 of 182) in 2024. A higher opioid share than 9 in 10 peers; the typical sleep medicine clinician is at 0%. Long-acting opioids: 96% of their opioid prescriptions.
175 generic and fewer than 11 brand-name prescriptions · $7,380 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Pregabalin | 28 | $1,181 | $42 |
| Doxepin | 15 | $375 | $25 |
| Midodrine | 11 | $321 | $29 |
| Methadone | 20 | $230 | $11 |
| Gabapentin | 20 | $179 | $9 |
See all 8 drugs
| Pregabalin | 28 | $1,181 | $42 |
| Doxepin | 15 | $375 | $25 |
| Midodrine | 11 | $321 | $29 |
| Methadone | 20 | $230 | $11 |
| Gabapentin | 20 | $179 | $9 |
| Trazodone | 46 | $82 | $2 |
| Eszopiclone | 12 | $66 | $6 |
| Zolpidem | 13 | $54 | $4 |
Year by year
| 2024 | 182 | 47 | 14% (25) | None | $7,380 |
| 2023 | 77 | 23 | 18% (14) | None | $2,622 |
| 2022 | 166 | 62 | None | None | $17,448 |
| 2021 | 129 | 59 | 12% (16) | None | $14,889 |
| 2020 | 99 | 22 | None | None | $3,453 |
| 2019 | 47 | 16 | 0% (0) | None | $2,107 |
| 2018 | 141 | 27 | 0% (0) | 16% | $14,010 |
| 2017 | 103 | 28 | None | None | $4,406 |
| 2016 | 90 | 28 | None | None | $8,050 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 3 drugs
| Pregabalin | 17 | $292 | $17 |
| Methadone | 12 | $209 | $17 |
| Gabapentin | 15 | $119 | $8 |
2022: 4 drugs
| Carbidopa-Levodopa | 20 | $1,302 | $65 |
| Carbidopa | 11 | $1,178 | $107 |
| Topiramate | 21 | $201 | $10 |
| Gabapentin | 12 | $147 | $12 |
2021: 2 drugs
| Carbidopa-Levodopa | 19 | $1,490 | $78 |
| Gabapentin | 20 | $287 | $14 |
2020: 3 drugs
| Carbidopa-Levodopa | 22 | $1,355 | $62 |
| Levetiracetam | 13 | $496 | $38 |
| Clonazepam | 12 | $35 | $3 |
2019: 1 drug
| Carbamazepine Er | 11 | $854 | $78 |
2018: 5 drugs
| Felbamate | 12 | $1,864 | $155 |
| Levetiracetam | 24 | $507 | $21 |
| Divalproex Sodium Er | 15 | $457 | $30 |
| Atorvastatin | 19 | $172 | $9 |
| Topiramate | 23 | $106 | $5 |
2017: 1 drug
| Atorvastatin | 20 | $166 | $8 |
Money from drug and device companies
$580 in 2025
| 2025 | 4 | 8 | $150 | $580 |
| 2024 | 3 | 4 | None | $385 |
| 2023 | 2 | 4 | None | $253 |
| 2022 | 1 | 1 | None | $95 |
| 2019 | 2 | 2 | None | $138 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Jazz Pharmaceuticals | Xywav | $405 | 5 payments
|
| Resmed | Airsense | $95 | 1 payment
|
| Novo Nordisk | None | $58 | 1 payment
|
| Lilly USA | Zepbound | $22 | 1 payment
|
See all 8 published payments
| Jazz Pharmaceuticals | Meals · 2025-06-09 | None | $104 |
| Resmed | Education · 2025-05-28 | Airsense | $95 |
| Jazz Pharmaceuticals | Meals · 2025-04-22 | Xywav | $75 |
| Jazz Pharmaceuticals | Meals · 2025-04-03 | Xywav | $44 |
| Jazz Pharmaceuticals | Consulting · 2025-03-14 | Xywav | $150 |
| Lilly USA | Meals · 2025-01-30 | Zepbound | $22 |
| Jazz Pharmaceuticals | Meals · 2025-01-16 | Xywav | $31 |
| Novo Nordisk | Meals · 2025-01-10 | None | $58 |
See earlier years (2024, 2023, 2022, 2019)
2024: $385
| Jazz Pharmaceuticals | Xywav | $143 | 2 payments
|
| Avadel CNS Pharmaceuticals | Lumryz | $121 | 1 payment
|
| ZOLL Respicardia | Remede System | $121 | 1 payment
|
2023: $253
| Jazz Pharmaceuticals | Xywav | $227 | 3 payments
|
| AbbVie | Duopa | $26 | 1 payment
|
2022: $95
| Harmony Biosciences | Wakix | $95 | 1 payment
|
2019: $138
| Genentech USA | None | $121 | 1 payment
|
| Amgen | None | $17 | 1 payment
|
Checkups this office reported
16 measures · 2023
Medicare asked this office to report how often certain checkups happened in 2023. This is not a grade for the doctor. A specialist’s patients may not need every screening.
- Medicare’s overall office score
- 92.8 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
| Asked about smokingPatients asked about tobacco, with help to quit if they smoke | 39%That's less than half. | 31 |
| Blood pressure under controlPeople with high blood pressure whose reading was in a healthy range | 73%That's more than half. | 319 |
| Breast cancer screeningEligible women who got a mammogram | 78%That's most of the people this applied to. | 199 |
| Cervical cancer screeningEligible women who got a Pap or HPV test | 40%That's less than half. | 324 |
| Checked for fall riskOlder patients screened for fall risk | 43%That's less than half. | 196 |
| Closing the Referral Loop: Receipt of Specialist ReportAs Medicare defines this measure | 29% | 641 |
| Colon cancer screeningEligible adults who got a colon cancer test | 42%That's less than half. | 546 |
| Depression screeningPatients screened for depression, with a follow-up plan if needed | 14%That's few of the people this applied to. | 656 |
See the other 8 measures
| Diabetes eye examPeople with diabetes who got a retinal eye exam | 10%That's few of the people this applied to. | 111 |
| Diabetes poorly controlledPeople with diabetes whose blood sugar stayed very high | 15%That's few of the people this applied to. Better on this measure. | 111 |
| Medications listed in the chartVisits where the current medication list was documented | 84%That's most of the people this applied to. | 1,741 |
| Patients can see their records onlinePatients who were given electronic access to their health information | 100%That's most of the people this applied to. | 439 |
| Risky medications in older adultsOlder patients given a medication that is risky at their age | 18%That's few of the people this applied to. Better on this measure. | 212 |
| Screening for High Blood Pressure and Follow-Up DocumentedAs Medicare defines this measure | 32% | 998 |
| Statin prescribed when it protects the heartPeople at cardiovascular risk who were prescribed a statin | 72%That's more than half. | 283 |
| Weight checked, with a follow-up planPatients whose BMI was recorded and followed up if needed | 36%That's less than half. | 947 |
What the office says it does
Boxes the office ticked on its Medicare worksheet for 2023. Nobody checks these.
- Agreed to federal review of their records system
- Checks the state prescription-drug database before prescribing
- Collects patient feedback
- Did a security review of patient data
- Exchanges records both ways with other health systems
- High Priority Practices Guide of the Safety Assurance Factors for EHR Resilience (SAFER) Guides
- Provide 24/7 Access to MIPS Eligible Clinicians or Groups Who Have Real-Time Access to Patient's Medical Record
- Reports cases to public health electronically
- Reports immunizations to the state registry
- Reports to a public-health or clinical registry
- Reports to public-health surveillance
Professional record
- NPI
- 1164872651
- Licence
- WA MD61157048Washington MD.MD.61157048: Active
- Trained
- Washington University School of Medicine, 2016
- Group
- King County Public Hospital District No 2 · Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2084S0012X (2084S0012X); Neurology (2084N0400X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2016-06-15
- NPI last updated
- 2026-03-24
- NPI record certified
- 2026-03-24
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 11521 Ne 128th St, Ste 130, Ms-12, Kirkland, WA, 98034 · 300 Pasteur Dr, Stanford, CA, 94305